Segment and Enterprise Wide Disclosures

3 Months Ended

Jun. 30, 2014

Segment and Enterprise Wide Disclosures

Note 10. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 65% and 74% of the Company’s total consolidated assets are located within the U.S. as of June 30, 2014 and March 31, 2014, respectively. The remaining assets are located primarily in Germany and include goodwill of $37.7 million and $35.4 million at June 30, 2014 and March 31, 2014, respectively, associated with the Impella acquisition in May 2005. Total assets outside of the U.S. excluding goodwill amounted to 17% and 8% of total consolidated assets as of June 30, 2014 and March 31, 2014, respectively. International sales (sales outside the U.S. and primarily in Europe) accounted for 11% and 8% of total revenue for the three months ended June 30, 2014 and 2013, respectively.